Half Year Results 

Tissue Regenix buys CellRight Technologies

Tissue Regenix buys CellRight Technologies

It’s been a “transformational” year for Tissue Regenix (TRX), or so says management. The medical devices company raised £40m through a share placing and used a chunk of the money to buy CellRight Technologies, a US-based medical company. CellRight’s regenerative platform technology focuses on bone procedures, but has other applications in orthopaedics, spinal and general surgery. This is complementary to Tissue Regenix's soft-tissue-based dCELL platform.

To continue reading, subscribe today

and enjoy unlimited access to the following:

  • Tips of the Week
  • Funds coverage
  • Weekly features on big investment themes
  • Trading ideas
  • Comprehensive companies coverage
  • Economic analysis
Subscribe
Subscribe to Investors Chronicle

Subscribe today

Full access for just £3.37 a week:

• Tips and recommendations - to beat the market 
• Portfolio clinic & Mr Bearbull - build a well-planned portfolio 
• Expert tools - track and manage investments effortlessly
• Plus free delivery to your home or office

Subscribe Now